The ALOX5 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the human ALOX5 gene. This polyclonal population is generated by CRISPR/Cas9-mediated gene disruption in the HAP1 cell background, providing a heterogeneous pool of edited cells that collectively abolish ALOX5 expression without relying on a single clonal isolate. The product is specifically formatted as polyclonal knockout cells, avoiding the selection bias inherent to monoclonal lines, and is well-suited for applications requiring robust, reproducible genetic perturbation in a leukotriene-relevant context. The knockout model enables investigation of ALOX5-dependent signaling and lipid mediator production across diverse experimental paradigms in immunology and cancer biology.
The host cell line HAP1 is a near-haploid human chronic myeloid leukemia cell line derived from the KBM-7 line, with male origin and a haploid karyotype except for a disomy of chromosome 8. This near-haploid genome simplifies genetic manipulation because a single CRISPR-mediated allele disruption can produce a functional knockout, enhancing the efficiency and completeness of gene editing in polyclonal pools. HAP1 cells retain key signaling pathways and have been widely adopted for genetic screens, knockout characterization, and mechanistic studies, making them a versatile platform for interrogating gene function in an isogenic background.
ALOX5 encodes arachidonate 5-lipoxygenase, the rate-limiting enzyme that catalyzes the sequential oxygenation of arachidonic acid to 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and its subsequent dehydration to leukotriene A4 (LTA4). LTA4 is further metabolized by LTA4 hydrolase to leukotriene B4 (LTB4) or by LTC4 synthase to cysteinyl leukotrienes (LTC4, LTD4, LTE4). These lipid mediators activate cognate G-protein-coupled receptors: LTB4 binds BLT1 and BLT2, while cysteinyl leukotrienes act on CysLT1 and CysLT2, driving pro-inflammatory responses, chemotaxis, and vasoconstriction. Upstream regulators of ALOX5 include intracellular calcium, 5-lipoxygenase activating protein (FLAP, encoded by ALOX5AP), MAP kinase-activated protein kinase 2 (MAPKAPK2/MK2), protein kinase A (PKA), and Src family kinases. Cytokines such as IL-3, GM-CSF, and IL-5 also modulate ALOX5 activity. The enzyme interacts with FLAP, LTA4 hydrolase, LTC4 synthase, coactosin-like protein (CLP), and phospholipase A2, integrating signals into the NF-??B and eicosanoid cascades.
In the HAP1 context, the near-haploid genome facilitates efficient disruption of ALOX5, creating a strong loss-of-function model that is particularly useful for dissecting leukotriene biosynthesis and its downstream effector pathways. The polyclonal nature of the knockout population minimizes clonal artifacts and preserves a representative distribution of editing events, enhancing biological reproducibility. This system allows researchers to directly link ALOX5 ablation to alterations in lipid mediator profiles and receptor-mediated signaling without the confounding effects of diploid compensation. Consequently, the cells are a powerful tool for interrogating ALOX5-dependent mechanisms in inflammation, cancer, and vascular biology within a genetically tractable background.
These polyclonal knockout cells are suited for a broad range of translational research applications, including functional studies of leukotriene signaling, target validation for 5-lipoxygenase inhibitors, and genetic screens for regulators of lipid mediator production. They support mechanistic investigations into inflammatory diseases such as asthma, atherosclerosis, and inflammatory bowel disease, as well as cancer types like colorectal and prostate cancer. Representative assays include Western blotting for ALOX5 protein, RT-qPCR for transcript analysis, ELISA and mass spectrometry for leukotriene quantification, immunofluorescence to monitor nuclear translocation, calcium flux and chemotaxis assays, NF-??B reporter assays, and flow cytometry-based phenotyping. For additional technical specifications or customized inquiries, please contact Ascent Research.
